I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment

Jose Perez-Garcia; Maria Gion; Javier Cortes

doi:10.1016/j.ccell.2021.06.008

I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment

Cancer Cell. 2021 Jul 12;39(7):902-904. doi: 10.1016/j.ccell.2021.06.008.

Authors

Jose Perez-Garcia¹, Maria Gion², Javier Cortes³

Affiliations

¹ Oncology Department, International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA.
² Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
³ Oncology Department, International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA; Breast Cancer Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. Electronic address: jacortes@vhio.net.

PMID: 34256905
DOI: 10.1016/j.ccell.2021.06.008

Abstract

I-SPY2 platform-based phase II studies in breast cancer might speed up the development of new treatments. In this issue of Cancer Cell, Pusztai et al. report that adding durvalumab and olaparib to standard neoadjuvant chemotherapy significantly increases the pathological complete response rate in patients with HER2-negative breast cancer irrespective of the hormone receptor status.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Female
Humans
Neoadjuvant Therapy
Phthalazines
Piperazines

Substances

Antibodies, Monoclonal
Phthalazines
Piperazines
durvalumab
olaparib